Summary of Clinical Use

Approved to treat acute hyperuricaemia, a pathological symptom of tumour lysis syndrome (TLS).

Mechanism Of Action and Pharmacodynamic Effects

Patients receiving chemotherapy for hematologic cancers such as leukemias and lymphomas are susceptible to developing tumour lysis syndrome (TLS). TLS arises from the build up of breakdown products of dying cancer cells, and results in hyperkalemia, hyperphosphatemia, hyperuricemia and hyperuricosuria and hypocalcemia, which can lead to renal failure. Rasburicase catalyses the metabolism of excess existing uric acid to allantoin, a more soluble and more easily excreted compound, reducing the renal load.

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)